Joseph Mahady has been appointed president, global business, Wyeth Pharmaceuticals and senior vice president, Wyeth. Mr. Mahady will continue to report to Bernard Poussot, president, chief operating officer and vice chairman of Wyeth.

In his new role, Mr. Mahady assumes operational responsibility for the company's global pharmaceutical business, including Europe/Middle East/Africa, Asia/Pacific, and Wyeth Nutrition, in addition to his current responsibilities for the Americas and the four strategic global business units: Pharmaceuticals, BioPharma, Vaccines and Women's Health Care.

Mr. Mahady joined the company in 1979 as a pharmacist in regulatory affairs. He has held several key commercial positions. He was appointed president, U.S. in 1995 and has since assumed responsibilities for the remainder of the Americas and for the global business units.

Also, Geno Germano has been appointed president, U.S. and general manager, Wyeth Pharmaceuticals. In this new role, Mr. Germano will continue to report to Mr. Mahady.

Mr. Germano joined the company in 1984 as a sales representative and has held positions of increasing responsibility in sales, marketing, business development and general management, including managing director, Wyeth Australia and New Zealand; executive vice president and general manager for Wyeth Global Vaccines; and most recently, executive vice president, Pharmaceutical Business Unit.

A Danish court has granted a preliminary injunction against Nomeco A/S, a pharmaceutical wholesaler in Denmark, prohibiting the sale of a generic version of Pfizer's Lipitor by Ranbaxy. The injunction, issued by the Copenhagen City Court in Denmark and subject to appeal by Nomeco, requires Ranbaxy's generic atorvastatin product to be withdrawn from the Danish market pending the outcome of a patent infringement trial that has not yet been scheduled.

The court ruled in Pfizer's favor on the three patents, atorvastatin calcium, the active ingredient in Lipitor, as well as processes and intermediate compounds used to make atorvastatin. The latest expiring patent provides coverage for Lipitor through November 2011.

"This ruling is another significant milestone in our defense of Lipitor patents around the world," said Pfizer's senior vice president and general counsel Allen Waxman. "And it's an important outcome for Pfizer and other medical innovators who invest in high-risk research to develop life-saving medicines for millions of patients," added Karin Verland, country manager of Pfizer Denmark.

Johane Boucher-Champagne, executive vice president, early clinical development of PharmaNet Development Group, has been appointed president and chief executive officer of the company's subsidiary, Anapharm, Inc., effective March 18, 2007. Ms. Boucher-Champagne will report to Mark Di Ianni, the company's president of early stage operations.

“Johane provided valuable assistance during the transition of the early stage business during the past year,” commented Mark Di Ianni. “Her energy, integrity and leadership skills have been demonstrated over the many years that she has contributed to the growth and development of Anapharm.”

Ms. Boucher-Champagne was appointed to her most recent position at PharmaNet in March 2006, where she provided senior leadership on global phase I and early stage business development. She has been serving as acting president and chief executive officer of Anapharm since December 2006. Previously, she served as chief operating officer of Anapharm.

Also, Dr. Marc LeBel will be leaving the company on March 18, 2007. He has served as president and chief executive officer of Anapharm since March 2002 and has held the position of executive vice president, bioanalytical laboratories, PharmaNet Development Group, since March 2006.

News from our sister sites